[ Inside the business ]

DNA stock analysis

DNA · Ginkgo Bioworks Holdings, Inc.

Biological products, (no diagnostic substances). Shrinking 6%.

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#5 of 20 mentioning it
03 Will customers keep buying?Sales −6%, steady
One Customer 15%Everyone else
Backlog $126M · 1.0× salesPrepaid $6MSales −6%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
06 Can it fund itself?0.5 yrs of cash
05 yrs10+ yrs
Shares +6.8%/yrDebt $0
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth −49%, −48%, then −6% vs. a year ago.

What could go wrong

Red flags.

It has moved 1.7× the market. In the 2022 rate shock it fell 62% while the market fell 24%. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Speculative.

Speculative: operating loss, cash flowing out of operations, under $1B in sales. Cash runway: 0.5 years.

What they sell

78% Cell Engineering Revenue.

Cell Engineering Revenue 78% · Service 22%

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Decline.

It's losing cash from operations and selling assets.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

0 of 7 years.

Returns beat its 11.7% cost of capital in 0 of the last 7 years.

Future bets

143% on research.

$187M a year on R&D. $7M on equipment and buildings.

All figures from Ginkgo Bioworks Holdings, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.